期刊文献+

糖尿病患者感染产ESBLs肠杆菌科细菌的耐药性及危险因素分析 被引量:4

Analysis of the Drug Resistance and Risk Factors of ESBLs-Producing Enterobacteriaceae Infection in Diabetics
下载PDF
导出
摘要 目的了解中山市糖尿病患者感染产超广谱β-内酰胺酶(extended spectrumβ-Lactamases,ESBLs)肠杆菌科细菌的耐药性及危险因素。方法收集2014年1月~2016年6月中山大学附属中山医院120例确诊糖尿病并发感染产ESBLs肠杆菌科细菌患者的临床标本132例和临床资料。通过VTIEK 2COMPCT全自动微生物鉴定系统进行菌种鉴定和药物敏感试验;使用VITEK 2COMPCT高级专家系统判定菌株的耐药表型和耐药模式,同时根据是否产ESBLs,把主要致病菌大肠埃希菌分为ESBLs-positive组和ESBLs-negative组,比较两组在耐药模式之间的区别。对患者的各项临床资料进行logistic回归分析糖尿病并发感染产ESBLs肠杆菌科细菌的危险因素。结果糖尿病患者感染产ESBLs肠杆菌科细菌主要是大肠埃希菌,其次是肺炎克雷伯菌,感染标本来源主要是中段尿。大肠埃希菌和肺炎克雷伯菌对厄他培南和亚胺培南敏感度为100%,对头孢替坦和哌拉西林/他唑巴坦的敏感度大于98%。大肠埃希菌ESBLs-positive组和ESBLsnegative组在获得性青霉素酶、β-内酰胺类抗生素野生型、其他超广谱β-内酰胺酶和CTX-M型ESBLs四种耐药模式之间差异均有统计学意义(χ~2=17.34,19.23,33.90,42.75,均P<0.05)。经logistic回归分析,年龄、住院次数、性别、糖尿病病程、收缩压、糖化血红蛋白水平、抗生素使用情况、感染前的治疗情况、类固醇药物应用、外科手术、侵入性操作、并发症等均不是产ESBLs肠杆菌科细菌感染的危险因素。结论大肠埃希菌和肺炎克雷伯菌是糖尿病患者感染产ESBLs肠杆菌科的主要致病菌,感染部分主要是泌尿系统。产ESBLs肠杆菌对厄他培南、亚胺培南、头孢替坦和哌拉西林/他唑巴坦敏感。大肠埃希菌ESBLs-positive组和ESBLs-negative组主要表现为四种耐药模式的差异。年龄、住院次数和性别等常见因素均不是糖尿病患者感染产ESBLs肠杆菌科细菌的危险因素。 Objective To study the drug resistance and risk factors for ESBLs producing Enterobacteriaceae infection in dia betics in Zhongshan. Methods 132 strains and clinical data were collected from January 2014 to June 2016 in 120 diabetes with Enterobacteriaceae bacteria infection in the Sun Ya^sen Hospital Affiliated to Sun Ya〉sen University. VTIEK 2 COMPCT automatic microbial identification system was used to identify strains and test drug sensitivity. The resistance phe notype and resistance pattern of the strain were determined by VTIEK 2 COMPCT advanced expert system. According to whether ESBLs was produced,the main pathogenic bacteria of Escherichia coli was divided into the ESBLs positive group and the ESBLs negative group,then compared the differences between the two groups in drug resistance patterns. Logistic regression was performed to analyze the risk factors for ESBLs producing Enterobacteriaceae infection in diabetics. Results The main pathogenic bacteria of diabetes patients with ESBLs producing infection was Escherichia coli, followed by Kleb- siella pneumoniae. The main source of infection was middle-stage urine. F.scherichia coli and Klebsiella pneumonia bacteria were sensitive to Ertapenem and Imipenem, the susceptible rate to cefotetan and Piperacillin/Tazobactam was higher than 98 G. Four modes of resistances (Acquired penieillinase, Wild betalaetam antibiotic, other ESBLs, ESBLs (CTX M LIKE)) had significant differences between the ESBLs positive and ESBLs negative groups (x2 = 17.34,19.23,33.90,42.75, all P〈0.05). Through logistic regression analysis, age, times of hospitalization, sex, diabetes duration, blood pressure, hemoglobin Alc levels,the usage of antibiotics,infection before the treatment and application of steroid and surgery, invasive operation and complications were not the risk factors of ESBLs infection. Conclusion Escherichia coli and Klebsiella pneumoniae were the main pathogenic bacterias of ESBLs producing Enterobacterlaceae in diabetic patients. The infection was mainly in the urinary system. ESBLs producing Enterobacteriaceae were sensitive to Ertapenem, Imipenem, Cefotetan and Piperacillin/ Tazobactam. Four modes of resistances had significant differences between the ESBLs positive and ESBLs negative groups. Age, the times of hospitalization, gender and other common factors were not the risk factors of the infection of ESBLs producing Enterobacteriaceae bacteria in diabetic patients.
作者 严海忠 王娟 卢兰芬 冯雪琴 YAN Hai zhong;WANG Juan;LU Lan fen;FEN Xue qin(the Center for Medicine Laboratory,Sun Yat-sen Hospital Affiliated to Sun Yat-sen University,Guangdong Zhongshan 528403,China)
出处 《现代检验医学杂志》 CAS 2018年第5期82-86,共5页 Journal of Modern Laboratory Medicine
关键词 糖尿病 超广谱Β-内酰胺酶 耐药 危险因素 cliabetics extenclecl spectrum lactamases clrug resistance risk {actor
  • 相关文献

参考文献5

二级参考文献66

  • 1Bader MS.Diabetic foot infection[J].Am Fam Physician,2008;78(1):71-19.
  • 2Lipsky BA.New developm ents in diagnosing and treating diabetic footinfections[J].Diabetes Metab Res Rev,2008;24(1):66-71.
  • 3李娟,于保荣.疾病经济负担研究综述[J].中国卫生经济,2007,26(11):72-74. 被引量:86
  • 4张卓然.临床微生物学和微生物检验[M].5版.北京:人民卫生出版社.2007.
  • 5Clinical and Laboratory Standards Institute(CLSI). Performance standards for antimicrobial suscptibility testing- Nineteenth informational supplement [S].Wayne : PA,CLSI, M100-S18. 2008 : 38-42.
  • 6Kandemir O,Akbay E,Sahin E,et al. Risk factors for infec- tion of the diabetic foot with multi-antibiotic resistant micror- ganisms[J3. J Infect,2007,54(5) :439-445.
  • 7Fouts DE,Torralba M,Nelson KE,et al. Bacterial transloca- tion and changes in the intestinal microbiome associated with alcoholic liver diseasel-J:. J Hepatol, 2012,56 (6) : 1283-1292.
  • 8Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teieoplanin for nosoeomial pneumonia: meta-analysis of ran- domised controlled trials[J]. Eur J Clin Microbiol Infect Dis, 2013,32(9) : 1121-1128.
  • 9Mohammadi S,MacKay K,Ward TT,etal. Clinical outcomes of a veterans affairs outpatient antimicrobial treatment pro- gram[J]. South Med J, 2013,106 (6) : 345-349.
  • 10Guariguata L, Nolan T, Beagley J, et al. IDF (International Dia- betes Federation) Diabetes Atlas,the 6th Edition. International Diabetes Federation, 2013.

共引文献308

同被引文献54

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部